Feb 20 (Reuters) - Prometic Life Sciences Inc PLI.TO :
* PROMETIC ANNOUNCES REALIGNMENT OF ITS CLINICAL PROGRAM PRIORITIES FOR 2018
* PROMETIC LIFE SCIENCES - AS PART OF REALIGNMENT, CO TERMINATED PBI-4050 CLINICAL TRIAL IN CYSTIC FIBROSIS RELATED DIABETES
* PROMETIC LIFE SCIENCES INC - AS PART OF REALIGNMENT, CO IS EVALUATING NEED TO CONTINUE OTHER ON-GOING CLINICAL PROGRAMS WITH PBI-4050
* PROMETIC LIFE SCIENCES-EVALUATING CLINICAL DEVELOPMENT STRATEGY REGARDING FOLLOW-ON COMPOUNDS WHICH SHARE SAME UNIQUE MECHANISM OF ACTION WITH PBI-4050